This EASL Studio has been shining the spotlight on news straight from the AASLD Liver Meeting. Watch the transatlantic discussion on key emerging concepts and the presentations that kept our experts on the edge of their seats.

Time Title

Welcome and introductions

Aleksander Krag, Odense University Hospital, Denmark

Raymond T. Chung, Massachusetts General Hospital, USA


Topic 1: News with clinical impact – NASH/NAFLD drug development

Meena Bansal, Icahn School of Medicine at Mount Sinai, USA


Topic 2: News with clinical impact: Viral Hepatitis B - Novel drug development

Joseph Lim, Yale University School of Medicine, USA


Hot topics at ILC 2022

Aleksander Krag, Odense University Hospital, Denmark



Aleksander Krag Aleksander Krag, MD, PhD, MBA, is Professor and Head of Hepatology and Director of Odense Liver Research Centre at Odense University Hospital. He is also Chair of Health Sciences at the Danish Institute of Advanced Studies (DIAS) at University of Southern Denmark, Associate editor at Danish Medical Journal and Editor in Chief at He holds leader positions in a number of research collaborations including being the director of the Fibrosis Fatty Liver and Steatohepatitis (FLASH) Research Centre Odense, and is involved in several international organisational activities. Research is his passion with a focus on liver fibrosis, complications to cirrhosis, alcoholic liver disease and microbiome.
Raymond Chung Dr Raymond Chung is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at Massachusetts General Hospital. He is also Professor of Medicine at Harvard Medical School. He has been an internationally recognized leader in HCV virology, pathogenesis, and hepatocarcinogenesis. In addition, he has been an Associate Editor of Hepatology, Gastroenterology, and the Journal of Infectious Diseases, and is currently President of the American Association for the Study of Liver Diseases (AASLD).




Meena Bansal Dr Bansal is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Secretary for AASLD, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis and NASH.
Joseph Lim Dr Lim is a Professor of Medicine and Vice-Chief of the Section of Digestive Diseases at Yale University, where he serves as Director of Clinical Hepatology and Associate Chief of Yale-New Haven Health System (YNHHS) Digestive Health. In his role at Yale Liver Center, he directs an active clinical trials program evaluating novel investigational agents for viral hepatitis and NASH. He serves on the AASLD CME Committee (Chair), Scientific Program Committee, and Viral Hepatitis Elimination Taskforce.